QNTM
Quantum Biopharma Ltd. Class B Subordinate Voting SharesQNTM
QNTM
About: Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Employees: 7
0
Funds holding %
of 7,324 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
116% more capital invested
Capital invested by funds: $256K [Q4 2024] → $553K (+$296K) [Q1 2025]
56% more funds holding
Funds holding: 9 [Q4 2024] → 14 (+5) [Q1 2025]
0.01% more ownership
Funds ownership: 3.63% [Q4 2024] → 3.64% (+0.01%) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for QNTM.
Financial journalist opinion
Based on 3 articles about QNTM published over the past 30 days
Neutral
GlobeNewsWire
4 hours ago
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced that Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms – today announced the launch of its previously announced Regulation D 506(c) offering to raise up to US$5.0 million to fund growth and establish a path to a possible initial public offering.
Neutral
Benzinga
20 hours ago
Quantum BioPharma Shares' Rollercoaster Day: What's Going On?
Shares of Quantum BioPharma Ltd QNTM started Wednesday with a surge before dropping, then heading back up slightly, despite a lack of company-specific news for the session. The biopharmaceutical company last week announced it had purchased 2,000 shares of GameStop Corp GME as a strategic investment for its balance sheet.
Neutral
GlobeNewsWire
1 week ago
Quantum BioPharma Makes Strategic Investment in GameStop Corp.
TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announced the purchase of 2,000 shares of GameStop Corp. (NYSE: GME) to hold on the Company's balance sheet as a strategic investment.
Neutral
GlobeNewsWire
1 month ago
Quantum BioPharma Announces Private Placement
TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it is completing a non-brokered private placement of class A multiple voting shares (“MVS”) at a price of $50 per MVS, for aggregate gross proceeds of up to $600 (the “Offering”). The Company expects that the entirety of the Offering will be subscribed for by the existing holders of MVS.
Neutral
GlobeNewsWire
1 month ago
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise
Neutral
Newsfile Corp
1 month ago
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies, today released its analysis of Quantum BioPharma Ltd.'s (NASDAQ: QNTM) continued progress across its innovative pipeline of treatments for brain disorders and alcohol health.
Neutral
GlobeNewsWire
1 month ago
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302 Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302
Neutral
GlobeNewsWire
1 month ago
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce its intention to declare a special dividend consisting of Contingent Value Rights (the “CVRs”) to be issued on a 1:1 basis to holders of the Company's Class B Subordinate Voting Shares.
Neutral
GlobeNewsWire
1 month ago
Quantum BioPharma Clarifies It Has Not Changed Its Name
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces its response to information about certain stock trading platforms as well as misinformation being circulated on certain social media channels. Certain stock trading platforms mistakenly have the Quantum BioPharma name changed to Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) after the news release was issued on May 29, 2025. Quantum BioPharma has not changed its name.
Neutral
GlobeNewsWire
1 month ago
iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients
Study Aims to Expedite Potentially Transformative Therapies By Assessing Safety and Efficacy of FSD202 Study Aims to Expedite Potentially Transformative Therapies By Assessing Safety and Efficacy of FSD202
Charts implemented using Lightweight Charts™